With it’s “biobank of blood donors” founded in 2006, that actually contains about 4 millionsamples, the Bavarian Red Cross is involved in several research projects on the earlydiagnosis of disease. The blood samples collected in the biobank are ideal for theidentification of biomarkers that become evident in the very early stages of disease. Thesubject of the latest (and largest) project is the development of a new testing method for theearly diagnosis of diabetes.
The actual number persons suffering from diabetes in Germany is about 8 million with a yeargrowth ratio of approximately 5%. With an overall treatment cost of 15 billion € per year,diabetes is one of the most common diseases of civilization.
Nuclear Magnetic Resonance (NMR) is a state of the art spectroscopy method based on thedetection of interactions of atomic nuclei and a magnetic field. The method is especiallysuitable for the rapid and precise analysis of biofluids (e.g. blood samples) containing acomplex mixture of macromolecules. LipoFIT now applies this forward-looking technology atlarge scale for the screening of the biobank. The data on the samples is then analyzed forthe identification of a set of Biomarkers suitable for the early detection of the disease.
Especially adult onset diabetes is expected to be diagnosed at a very early stage. Nowadaysit often remains undiscovered for a long time, because a person affected does not showsignificant symptoms while the body already suffers irreversible damage.
For further information please contact:
Christiane Proll MBA
numares GmbH
Josef- Engert- Str. 9
93053 Regensburg
Tel.: +49 941 280949-14
Email: christiane.proll(at)numares.com